熱門資訊> 正文

诺华扩大了普卢维托的适应症

2026-08-01 05:26

諾華製藥(NVS) 0

The US FDA has approved an expanded indication for Novartis' (NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) so that it can be used across all stages of PSMA-positive metastatic prostate cancer.
The drugmaker noted that the approval will almost double the eligible patient population.
Approval was granted based on results from the phase III PSMAddition trial that showed Pluvicto reduced the risk of progression or death by 28% when combined with standard of care compared to standard of care alone.

More on Novartis

Novartis: The Buy Thesis Is Back (Rating Upgrade)
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon
Novartis rises as Q2 results beat on both lines
Novartis beats top-line and bottom-line estimates; reaffirms FY26 outlook

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。